Abemaciclib - Eli Lilly and Company
Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY 2835219; Verzenio; VerzeniosLatest Information Update: 27 Feb 2024
At a glance
- Originator Eli Lilly and Company
- Developer Boehringer Ingelheim; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center; Washington University School of Medicine
- Class Aminopyridines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III Liposarcoma; Prostate cancer
- Phase II Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Glioblastoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
- Phase I/II Head and neck cancer
- Phase I Myelofibrosis
- No development reported Cancer; Renal cell carcinoma
Most Recent Events
- 21 Feb 2024 Discontinued - Phase-II for Prostate cancer (Second-line therapy or greater, Metastatic disease, Hormone refractory) in Spain, USA and Australia (PO)
- 21 Feb 2024 Discontinued - Phase-III for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in China Denmark Germany Japan Netherlands Puerto Rico Romania South Korea Spain USA United Kingdom France Spain USA (PO)
- 16 Feb 2024 MedSIR plans a phase II trial for Breast cancer (Monotherapy, Combination therapy; Adjuvant therapy) in (PO) in 1st March 2024 (NCT05708235) (EudraCT2022-002616-24)